This company has been marked as potentially delisted and may not be actively trading.

Hologic (HOLX) Stock Forecast & Price Target

Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HOLX Analyst Ratings Over Time

Type	Current Forecast 9/10/25 to 9/10/26	1 Month Ago 8/11/25 to 8/11/26	3 Months Ago 6/12/25 to 6/12/26	1 Year Ago 9/10/24 to 9/10/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	8 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$79.13	$79.13	$79.09	$78.00
Forecasted Upside	4.10% Upside	4.10% Upside	4.05% Upside	19.08% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hologic Stock vs. The Competition

Type	Hologic	Healthcare Companies	Broader Market
Consensus Rating Score	2.00	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	4.10% Upside	920.98% Upside	16.49% Upside
News Sentiment Rating	Neutral News See Recent HOLX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
1/28/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Hold (C)
1/12/2026	Argus 3 of 5 stars	David Toung 4 of 5 stars	Downgrade	Buy ➝ Hold
1/5/2026	Evercore 3 of 5 stars	Vijay Kumar 3 of 5 stars	Downgrade	Outperform ➝ In-Line	$79.00 ➝ $78.00	+4.61%
11/21/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold	$79.00	+6.58%
11/11/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$69.00 ➝ $76.00	+1.88%
11/4/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
10/23/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$70.00 ➝ $78.00	+5.51%
10/22/2025	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mason Carrico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$78.00 ➝ $76.00	+2.75%
10/22/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
10/22/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$78.00	+5.43%
Get the Latest News and Ratings for HOLX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.
10/21/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Puneet Souda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$70.00 ➝ $78.00	+5.35%
10/21/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral
8/6/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Conor McNamara Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform	$72.00 ➝ $87.00	+28.28%
7/31/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Garcia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$65.00 ➝ $70.00	+4.19%
7/9/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00 ➝ $80.00	+23.27%
2/6/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
12/13/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Doug Schenkel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
12/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Hold	$85.00	+12.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:14 AM ET.

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 8, 2026. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

Here are some ways that investors could benefit from investing in Hologic, Inc.:

Hologic, Inc. is currently trading at $76.01, a price that sits just below the consensus price target of $78.42, suggesting potential for modest upside as the stock consolidates following its recent 52-week high of $76.07.
The company demonstrated strong financial performance in its most recent reported quarter, delivering an actual EPS of $1.04 and revenue of $1,047.8 million, which reflects a year-over-year revenue growth of 2.5% and indicates stable demand for its women's health diagnostics and imaging products.
Hologic, Inc. recently secured a significant legal victory where a court determined that Siemens infringed on Hologic's mammography patent, a development that strengthens the company's intellectual property position and could provide additional revenue or licensing opportunities in the breast health segment.
The company expanded the CE-IVDR mark for its Aptima HPV Test to include self-collected sample claims in cervical cancer screening, a regulatory milestone that broadens the test's utility and accessibility for patients, potentially driving higher adoption rates in the diagnostics segment.
New evidence presented at the Society of Breast Imaging Symposium backs Hologic's AI-powered mammography technology for detecting challenging cancers, reinforcing the company's leadership in medical imaging innovation and supporting the long-term value proposition of its breast health solutions.

Hologic
Bear Case

Investors should be bearish about investing in Hologic, Inc. for these reasons:

Hologic, Inc. is facing a major corporate transition as Blackstone and TPG have completed their acquisition of the company for up to $79 per share, which means the stock is set to go private and cease public trading, eliminating liquidity for current shareholders who have not sold.
The company is dealing with a product recall for its BioZorb needles, with the FDA citing 252 injuries, and a subsequent shortage of these needles used for breast cancer detection, which poses operational risks and potential reputational damage to the breast health segment.
The consensus rating for Hologic, Inc. has shifted to "Hold" as of April 2026, down from a "Moderate Buy" in late 2025, indicating that analysts are becoming more cautious about the stock's future performance relative to its current valuation.
Short interest in Hologic, Inc. has increased significantly in recent months, rising from 3.7 million shares in late 2025 to over 8.1 million shares by March 2026, suggesting that a growing number of investors are betting against the stock or hedging their positions.
The company's P/E ratio stands at 31.67, which is relatively high compared to many healthcare peers, and with the stock trading near its 52-week high, there is limited margin of safety for investors entering the position now.

HOLX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $79.13, with a high forecast of $90.00 and a low forecast of $76.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 12 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.

According to analysts, Hologic's stock has a predicted upside of 4.10% based on their 12-month stock forecasts.

Analysts like Hologic less than other "healthcare" companies. The consensus rating score for Hologic is 2.00 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how HOLX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Hologic Recommendations

MarketBeat monitors more than a dozen sources for Hologic analyst ratings, with the most recent rating issued on 1/28/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.